Calcifediol is a form of Vitamin D that your body makes in the liver. It helps your body absorb calcium, which is important for strong bones. Doctors measure calcifediol levels to check your Vitamin D status.
Every report comes from a Lived member, sent anonymously.
Have you tried Calcifediol for Secondary Hyperparathyroidism?
Calcifediol is a form of vitamin D sold in the US as Rayaldee, a prescription extended-release capsule. It treats secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease (CKD) whose vitamin D is low, defined as a 25-hydroxyvitamin D blood level below 30 ng/mL. The parathyroid glands are four small glands in the neck that make parathyroid hormone (PTH), which keeps calcium and phosphorus in balance. In secondary hyperparathyroidism, these glands make too much PTH in response to another problem, here failing kidneys. It is a common complication of CKD and disturbs how the body handles minerals and maintains bone. The active form of vitamin D normally helps hold PTH in check, so low vitamin D can add to the problem. Rayaldee is meant to restore vitamin D levels and bring PTH down. Rayaldee is not approved for people with stage 5 CKD or for people on dialysis. Doctors also treat secondary hyperparathyroidism with active vitamin D medicines such as calcitriol or paricalcitol. An older immediate-release calcifediol capsule, Calderol, was once sold in the US but has been discontinued.
Vitamin D from sunlight, food or supplements is not usable as it is. The liver first converts it into 25-hydroxyvitamin D, which is calcifediol, and this is also the form the standard vitamin D blood test measures. The kidneys then turn calcifediol into calcitriol, the active hormone. Calcitriol helps the gut absorb calcium and phosphorus and signals the parathyroid glands to make less PTH. Because Rayaldee supplies calcifediol directly, it raises the 25-hydroxyvitamin D level without depending on the liver step. The extended-release capsule releases the medicine gradually rather than all at once. In the clinical studies, PTH began to fall within the first two weeks, while vitamin D levels took about three months to level off.
Rayaldee comes as a 30 mcg extended-release capsule taken by mouth once a day at bedtime. Swallow the capsules whole. Treatment starts only when a blood test shows calcium below 9.8 mg/dL (milligrams per deciliter). About three months after starting, the prescriber rechecks calcium, phosphorus, vitamin D and PTH. If PTH is still above the goal and the other results are not too high, the dose may rise to 60 mcg (two capsules) once nightly. The aim is a 25-hydroxyvitamin D level between 30 and 100 ng/mL, normal calcium, and PTH within a range the prescriber sets; there is no single PTH target that fits everyone. Doses are paused and later restarted lower if PTH falls too far, calcium stays above normal, or vitamin D stays above 100 ng/mL. If you miss a dose, skip it and take the next one at the usual time. Do not take an extra dose to make up for it.
In the main trials, problems reported somewhat more often with Rayaldee than with placebo included anemia (a low red blood cell count), cold-like symptoms, constipation, cough, shortness of breath and a rise in creatinine, a blood marker of kidney function. Heart failure was also reported more often (3.5% versus 0.7%), so new or worsening shortness of breath or swelling is worth reporting. The main serious risk is hypercalcemia, meaning too much calcium in the blood. In the trials about 2 in 100 people needed a lower dose because of it. Signs include tiredness, trouble thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, urinating more and weight loss. Contact the care team promptly if these appear, since a blood test can show whether calcium is the cause. Severe hypercalcemia can disturb heart rhythm or cause seizures and may need emergency treatment.
Other sources of vitamin D and calcium matter most. High-dose calcium supplements, other vitamin D products (including over-the-counter vitamin D) and thiazide diuretics, a common type of water pill used for blood pressure, can all push calcium too high. Tell the prescriber about every supplement before starting. People taking digoxin, a digitalis heart medicine, need closer monitoring, because high calcium makes digoxin toxicity more likely. Cholestyramine, a cholesterol-lowering powder, can reduce how much calcifediol is absorbed, and phenobarbital and some other seizure medicines make the body clear it faster. Strong enzyme-blocking medicines, such as the antifungal ketoconazole or the HIV medicine ritonavir, can also change calcifediol levels. Starting or stopping any of these usually means extra blood tests and possibly a dose change. Lowering PTH too far causes its own harm. Very low PTH can lead to adynamic bone disease, a state in which bone stops renewing itself normally and fractures become more likely. This is one reason PTH is measured regularly and the dose is paused if it drops too low. There are no human data on calcifediol in pregnancy. It is not known whether it passes into breast milk, so a breastfed baby should be watched for signs of high calcium, such as vomiting, constipation, weight loss or seizures, and the baby's calcium may be checked.
The benefit of Rayaldee shows up in blood tests rather than in how you feel. Because vitamin D levels take about three months to settle, the first full check of calcium, phosphorus, vitamin D and PTH comes about three months after starting or after any dose change. After that, these tests are repeated at least every 6 to 12 months, and more often for people who have had high calcium before. In the two six-month trials that led to approval, about one in three people taking Rayaldee had PTH fall by at least 30%, compared with fewer than one in ten on placebo, and more than 80% reached a vitamin D level of at least 30 ng/mL. Those trials judged success by blood tests, not by fractures or other long-term outcomes. Comparisons with active vitamin D medicines such as paricalcitol are indirect, since no head-to-head trials have been published; they suggest similar PTH lowering, with paricalcitol raising calcium more. Calcifediol lingers in the body: in people with CKD, levels take about 25 days to fall by half. Its effects on calcium therefore do not stop the day a dose is skipped or paused. Because Rayaldee is not approved for stage 5 CKD or dialysis, the treatment plan needs review if kidney disease reaches that point.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Calcifediol, what you've noticed, or ask the community a question.